Patents matching “formulation”

US 10322094

Eutectic formulations of cyclobenzaprine hydrochloride and amitriptyline hydrochloride

TONIX PHARMA LIMITED · Granted Jun 18, 2019 · Expires Jun 13, 2039

US 10314790

Sustained-release formulations of topiramate

Supernus Pharmaceuticals, Inc. · Granted Jun 11, 2019 · Expires Jun 6, 2039

US 10307418

Azole pharmaceutical formulations for parenteral administration and methods for preparing and using the same as treatment of diseases sensitive to azole compounds

Platform Brightworks Two, Ltd. · Granted Jun 4, 2019 · Expires May 30, 2039

US 10300134

Vaccine formulations and methods of preparation and use thereof

Tejas Discovery and Research, LLC · Granted May 28, 2019 · Expires May 23, 2039

US 10293049

Etanercept formulations stabilized with amino acids

Coherus BioSciences, Inc. · Granted May 21, 2019 · Expires May 16, 2039

US 10286072

Methods of manufacturing stable aqueous formulations of adalimumab

Coherus BioSciences, Inc. · Granted May 14, 2019 · Expires May 9, 2039

US 10286071

Syringe containing stable aqueous formulations of adalimumab

Coherus BioSciences, Inc. · Granted May 14, 2019 · Expires May 9, 2039

US 10279015

TPP-1 formulations and methods for treating CLN2 disease

BIOMARIN PHARMACEUTICAL INC. · Granted May 7, 2019 · Expires May 2, 2039

US 10272039

Topical sodium nitrite formulation

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Apr 30, 2019 · Expires Apr 25, 2039

US 10272034

Auris formulations for treating otic diseases and conditions

The Regents of the University of California · Granted Apr 30, 2019 · Expires Apr 25, 2039

US 10265397

Formulation for photodynamic therapy

SANOCHEMIA PHARMAZEUTIKA AG · Granted Apr 23, 2019 · Expires Apr 18, 2039

US 10265319

Formulations of viloxazine

Supernus Pharmaceuticals, Inc. · Granted Apr 23, 2019 · Expires Apr 18, 2039

US 10258635

Formulations and compositions of vitamin D analogs for treating and preventing cancer and other diseases

Aphios Corporation · Granted Apr 16, 2019 · Expires Apr 11, 2039

US 10258631

Formulations of testosterone and methods of treatment therewith

The Board of Regents of the University of Texas System · Granted Apr 16, 2019 · Expires Apr 11, 2039

AU 2017305856

Pharmaceutical formulations of C1 esterase inhibitor

CSL BEHRING GMBH [DE] · Granted Mar 21, 2019 · Expires Mar 16, 2039

US 10221226

LEDGF peptides and formulations thereof for treatment of degenerative disorders

The Regents of the University of Colorado, a Body Corporate · Granted Mar 5, 2019 · Expires Feb 28, 2039

US 10220093

Long-acting semi-solid lipid formulations

MIRA PHARMA CORPORATION · Granted Mar 5, 2019 · Expires Feb 28, 2039

US 10213508

Etanercept formulations stabilized with xylitol

Coherus BioSciences, Inc. · Granted Feb 26, 2019 · Expires Feb 21, 2039

US 10206932

Natural combination hormone replacement formulations and therapies

Compass Therapeutics LLC · Granted Feb 19, 2019 · Expires Feb 14, 2039

US 10206897

Creatine ester anti-inflammatory compounds and formulations

BOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA · Granted Feb 19, 2019 · Expires Feb 14, 2039

US 10207003

Liquid pentablock co-polymer formulations for sustained delivery of therapeutics

inovion, Inc. · Granted Feb 19, 2019 · Expires Feb 14, 2039

US 10207000

Stable aqueous formulations of adalimumab

Coherus BioSciences, Inc. · Granted Feb 19, 2019 · Expires Feb 14, 2039

US 10201499

Nanoparticle formulation

United Kingdom Research and Innovation · Granted Feb 12, 2019 · Expires Feb 7, 2039

US 10201609

Method for the production of a formulation of a hypericin salt

SANOCHEMIA PHARMAZEUTIKA AG · Granted Feb 12, 2019 · Expires Feb 7, 2039